Titan Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Titan Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Titan Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TTNP - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	0	-6	-7	-7	N/A
9/30/2023	0	-6	-6	-6	N/A
6/30/2023	0	-8	-6	-6	N/A
3/31/2023	0	-9	-7	-7	N/A
12/31/2022	1	-10	-8	-8	N/A
9/30/2022	1	-10	-8	-8	N/A
6/30/2022	1	-9	-8	-8	N/A
3/31/2022	1	-9	-8	-8	N/A
12/31/2021	2	-9	-8	-8	N/A
9/30/2021	3	-7	-11	-11	N/A
6/30/2021	4	-7	-13	-13	N/A
3/31/2021	4	-7	-15	-15	N/A
12/31/2020	5	-7	-18	-17	N/A
9/30/2020	4	-2	-17	-16	N/A
6/30/2020	4	-3	-16	-16	N/A
3/31/2020	3	-6	-17	-16	N/A
12/31/2019	3	-7	-16	-15	N/A
9/30/2019	4	-16	-16	-15	N/A
6/30/2019	4	-16	-14	-14	N/A
3/31/2019	6	-11	-12	-12	N/A
12/31/2018	7	-9	-9	-8	N/A
9/30/2018	5	-9	-9	-9	N/A
6/30/2018	4	-11	-10	-10	N/A
3/31/2018	1	-14	-11	-11	N/A
12/31/2017	0	-14	-13	-13	N/A
9/30/2017	0	-13	N/A	-12	N/A
6/30/2017	0	-11	N/A	-11	N/A
3/31/2017	15	4	N/A	5	N/A
12/31/2016	15	5	N/A	6	N/A
9/30/2016	15	5	N/A	7	N/A
6/30/2016	15	6	N/A	8	N/A
3/31/2016	1	-8	N/A	-7	N/A
12/31/2015	2	-11	N/A	-7	N/A
9/30/2015	3	-9	N/A	-7	N/A
6/30/2015	3	-7	N/A	-7	N/A
3/31/2015	4	-5	N/A	-6	N/A
12/31/2014	4	-2	N/A	-6	N/A
9/30/2014	4	-2	N/A	-6	N/A
6/30/2014	5	-4	N/A	-7	N/A
3/31/2014	6	2	N/A	-10	N/A
12/31/2013	10	10	N/A	-10	N/A
9/30/2013	13	10	N/A	2	N/A
6/30/2013	12	3	N/A	2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de TTNP es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de TTNP crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de TTNP crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de TTNP crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de TTNP crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TTNP se prevé que sea elevada dentro de 3 años.

Titan Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Analysts update estimates

Recent updates

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Insider recently bought US$1.7m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought US$348k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought US$157k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: US$2.88

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharma regains Nasdaq listing compliance

Titan Pharmaceuticals announces 1-for-30 reverse stock split

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals EPS misses by $0.01, beats on revenue

Titan Pharma closes debt settlement and JT-09 acquisition

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharma to raise $8M in stock offering

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

Analysts update estimates

New 90-day low - US$0.27

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento